Cargando…

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States

OBJECTIVES: The aim of this survey was to examine the experience of patients with neuroendocrine tumors (NETs) to raise awareness of the NET-related burden and identify unmet needs. Here, we report data from patients in the United States. METHODS: Patients with NETs participated in a 25-minute anony...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolin, Edward M., Leyden, John, Goldstein, Grace, Kolarova, Teodora, Hollander, Ron, Warner, Richard R.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404397/ https://www.ncbi.nlm.nih.gov/pubmed/28328615 http://dx.doi.org/10.1097/MPA.0000000000000818

Ejemplares similares

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
por: Singh, Simron, et al.
Publicado: (2016)

The Role of Patient Support Groups in Neuroendocrine Neoplasms
por: Kolarova, Teodora, et al.
Publicado: (2021)

Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals
por: Leyden, Simone, et al.
Publicado: (2019)

Patient Survey of the Physical, Emotional, and Informational Challenges for Patients Living with Neuroendocrine Tumors
por: Khan, Mohid S., et al.
Publicado: (2019)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

SUN-LB068 Ectopic Cushing Syndrome Due to a Metastatic Neuroendocrine Tumor Treated with Metyrapone
por: Tsomos, Effie, et al.
Publicado: (2019)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
por: Yao, James C, et al.
Publicado: (2017)

Delays and routes to diagnosis of neuroendocrine tumours
por: Basuroy, Ron, et al.
Publicado: (2018)

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention
por: Guccione, Lisa, et al.
Publicado: (2019)

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
por: Rodriguez-Freixinos, Víctor, et al.
Publicado: (2021)

Insights into gastric neuroendocrine tumors burden
por: Thomaz Araújo, Taíssa Maíra, et al.
Publicado: (2017)

At Preeclampsia Diagnosis, Total Cell‐Free DNA Concentration is Elevated and Correlates With Disease Severity
por: Kolarova, Teodora R., et al.
Publicado: (2021)

Burden of peripheral arterial disease in Europe and the United States: a patient survey
por: Marrett, Elizabeth, et al.
Publicado: (2013)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?
por: Derks, Jules L, et al.
Publicado: (2019)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
por: Wolin, Edward M., et al.
Publicado: (2013)

Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States
por: May, Michael S., et al.
Publicado: (2021)

Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
por: Zappa, Magaly, et al.
Publicado: (2017)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2020)

Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study
por: Zhu, Li-Ming, et al.
Publicado: (2016)

Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
por: Popper, Helmut, et al.
Publicado: (2021)

Treatment options for patients with large cell neuroendocrine carcinoma of the lung
por: Iyoda, Akira, et al.
Publicado: (2014)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

Large cell neuroendocrine carcinoma of the lung presenting as pseudoachalasia: a case report
por: Anaizi, Ahmad, et al.
Publicado: (2015)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial
por: Lombard-Bohas, Catherine, et al.
Publicado: (2015)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

Global burden of neuroendocrine tumors and changing incidence in Kentucky
por: Chauhan, Aman, et al.
Publicado: (2018)

HSD51 Differences in Disease Burden and Treatment Utilization By Socioeconomic Status Among a Large Cohort of Patients with COVID-19 Diagnosis in the United States
por: Wade, R., et al.
Publicado: (2023)

Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States
por: Shah, Shrunjal, et al.
Publicado: (2021)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors
por: Seo, Caroline, et al.
Publicado: (2022)

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung
por: Gu, Jianjun, et al.
Publicado: (2019)

Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma
por: Liang, Zuoyu, et al.
Publicado: (2022)

Pitfalls in neuroendocrine tumor diagnosis
por: Bajetta, Emilio, et al.
Publicado: (2009)

Diagnosis of Pancreatic Neuroendocrine Tumors
por: Lee, Dong Wook, et al.
Publicado: (2017)

The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease
por: Magrey, Marina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_78ksqkbkfc5lrieev3dshpbu3o